An observational study of olanzapine coated and orodispersible tablets effectiveness in schizophrenic and bipolar outpatients.

Trial Profile

An observational study of olanzapine coated and orodispersible tablets effectiveness in schizophrenic and bipolar outpatients.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Olanzapine (Primary)
  • Indications Bipolar disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Sep 2015 Results of post hoc analysis are presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
    • 05 Aug 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 05 Aug 2009 Actual patient number (1131) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top